Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen Meghna A Singhania30 April 2019 4:46 AM GMTGlenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.Mumbai: In a major relief to diabetics, Glenmark...
Pfizer gets EU nod to VIZIMPRO for treating lung cancer Farhat Nasim6 April 2019 4:10 AM GMTNew Delhi: Pfizer Inc. recently announced that the European Commission has approved VIZIMPRO (dacomitinib), a tyrosine kinase inhibitor (TKI), as...
Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate Meghna A Singhania31 March 2019 8:09 AM GMTNew Delhi: Mumbai-based Glenmark Pharmaceuticals Limited recently received the permission from the IND Committee of the Central Drugs Standard...
Roche drug cocktail doubles chance of holding lung cancer at bay Ruby Khatun Khatun9 Dec 2017 4:15 AM GMTZURICH: Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease...
Trial results of Zika vaccine Sanofi dropped show promise Ruby Khatun Khatun6 Dec 2017 4:15 AM GMTCHICAGO: A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of...
Takeda moves ahead in Zika race with launch of vaccine trial Ruby Khatun Khatun30 Nov 2017 4:00 AM GMTLONDON: Japan's Takeda Pharmaceutical has moved ahead in the race to develop a vaccine for the mosquito-borne Zika virus, with the start of a clinical...
Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs Ruby Khatun Khatun24 Nov 2017 4:00 AM GMTDenmark: Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its...
Roche win boosts case for adding chemo to cancer immunotherapy Ruby Khatun Khatun23 Nov 2017 4:00 AM GMTLONDON: Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them...
GSK appoints scientist Barron as new Research and Development head Ruby Khatun Khatun10 Nov 2017 4:17 AM GMTLONDON: GlaxoSmithKline (GSK) has poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head as new Chief...
Roche Perjeta regimen gets FDA priority review in breast cancer Ruby Khatun Khatun4 Oct 2017 3:50 AM GMTZURICH: The U.S. Food and Drug Administration (FDA) has granted a priority review for Roche's Perjeta in combination with Herceptin and chemotherapy...
Bristols drug cocktail cuts kidney cancer death risk 37 percent Ruby Khatun Khatun14 Sep 2017 3:55 AM GMTMADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
AstraZeneca rebuilds cancer drug hopes with new lung data Ruby Khatun Khatun12 Sep 2017 4:02 AM GMTMADRID: Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset...
